In plain language
In neuroendovascular procedures in children and adults, customized imaging protocols plus changes in operator behavior were associated with patient dose estimates falling by 50% or more. Staff dose was not measured, though lower patient dose usually means less scatter.
At a glance
- Type of study
- Original research, Retrospective cohort study
- Who was studied
- Patients, Phantom or simulation (no people)
- Summary based on
- the abstract
What it found
Customized imaging protocols combined with changes in personnel behavior reduced procedural dose estimates by half or more compared with vendor-recommended protocols.
Key figures: 50% or more
Combining equipment modification with operator behavior can substantially reduce radiation use in neuroendovascular procedures.
Limits to keep in mind
Retrospective before-after comparison with phantom work; abstract gives no sample size and measures patient dose only, not staff dose.
Related research summaries
- Patient And Staff Doses In Paediatric Interventional Cardiology Derived From Experimental Measurements With Phantoms (2015, Phantom or simulation study)
- Feasibility of using ultra-low pulse rate fluoroscopy during routine diagnostic coronary angiography (2018, Retrospective cohort study)
- Dose reduction for fluoroscopically guided injections: phantom simulation and patient procedures (2017, Retrospective cohort study)
- Optimisation of imaging protocols in interventional cardiology: impact on patient doses (2017, Original research)
- Improving safety in the electrophysiology laboratory using a simple radiation dose reduction strategy: a study of 1007 radiofrequency ablation procedures (2010, Prospective cohort study)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.